Literature DB >> 11741238

An interactive algorithm for the assessment of cumulative cortisol suppression during inhaled corticosteroid therapy.

S Krishnaswami1, G Hochhaus, H Derendorf.   

Abstract

The objective of the study was to develop an algorithm based on a pharmacokinetic-pharmacodynamic (PK/PD) modeling approach to quantify and predict cumulative cortisol suppression (CCS) as a surrogate marker for the systemic activity of inhaled corticosteroid therapy. Two Excel spreadsheets, one for single dose and another for steady-state multiple doses of inhaled steroids, were developed for predicting CCS. Four of the commonly used inhaled steroids were chosen for the purposes of simulation: fluticasone propionate (FP), budesonide (BUD), flunisolide (FLU), and triamcinolone acetonide (TAA). Drug-specific PK and PD parameters were obtained from previous single- and multiple-dose studies. In cases in which multiple-dose data were not available, the single-dose data were extrapolated. The algorithm was designed to calculate CCS based on 5 input parameters: name of drug, dose, dosing interval, time(s) of dosing, and type of inhaler device. In addition, a generalized algorithm was set up to calculate CCS based on clearance, volume of distribution, absorption rate, protein binding, pulmonary deposition, oral bioavailability, and unbound EC50 of the corticosteroid of interest. The spreadsheet allowed predictions of CCS for single doses as well as steady-state conditions. A simple method has been developed that facilitates comparisons between various drugs and dosing regimens and has the potential to significantly reduce the number of comparative clinical trials to be performed for evaluating the short-term systemic activity of inhaled corticosteroids.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11741238      PMCID: PMC2761133          DOI: 10.1208/ps020322

Source DB:  PubMed          Journal:  AAPS PharmSci        ISSN: 1522-1059


  14 in total

1.  Mathematical modeling of circadian cortisol concentrations using indirect response models: comparison of several methods.

Authors:  A Chakraborty; W Krzyzanski; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1999-02

2.  An assessment of the systemic effects of single and repeated doses of inhaled fluticasone propionate and inhaled budesonide in healthy volunteers.

Authors:  A Lönnebo; A Grahnén; B Jansson; R M Brundin; A Ling-Andersson; S A Eckernäs
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

3.  Dependency of cortisol suppression on the administration time of inhaled corticosteroids.

Authors:  B Meibohm; G Hochhaus; S Rohatagi; H Möllmann; J Barth; M Wagner; M Krieg; R Stöckmann; H Derendorf
Journal:  J Clin Pharmacol       Date:  1997-08       Impact factor: 3.126

4.  Systemic effects of inhaled fluticasone propionate and budesonide in adult patients with asthma.

Authors:  E Derom; J Van Schoor; W Verhaeghe; W Vincken; R Pauwels
Journal:  Am J Respir Crit Care Med       Date:  1999-07       Impact factor: 21.405

5.  An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers.

Authors:  A Grahnén; S A Eckernäs; R M Brundin; A Ling-Andersson
Journal:  Br J Clin Pharmacol       Date:  1994-12       Impact factor: 4.335

6.  A pharmacokinetic/pharmacodynamic approach to predict the cumulative cortisol suppression of inhaled corticosteroids.

Authors:  B Meibohm; G Hochhaus; H Möllmann; J Barth; M Wagner; M Krieg; R Stöckmann; H Derendorf
Journal:  J Pharmacokinet Biopharm       Date:  1999-04

7.  Pharmacokinetic and pharmacodynamic evaluation of triamcinolone acetonide after intravenous, oral, and inhaled administration.

Authors:  S Rohatagi; G Hochhaus; H Mollmann; J Barth; E Galia; M Erdmann; H Sourgens; H Derendorf
Journal:  J Clin Pharmacol       Date:  1995-12       Impact factor: 3.126

8.  Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate.

Authors:  S Rohatagi; A Bye; C Falcoz; A E Mackie; B Meibohm; H Möllmann; H Derendorf
Journal:  J Clin Pharmacol       Date:  1996-10       Impact factor: 3.126

9.  Time-dependent effects of dexamethasone administration on the suppression of plasma hydrocortisone, assessed with a pharmacokinetic model.

Authors:  R P Koopmans; M C Braat; B Oosterhuis; C J van Boxtel
Journal:  J Pharmacol Exp Ther       Date:  1992-08       Impact factor: 4.030

10.  Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects.

Authors:  A N Kong; E A Ludwig; R L Slaughter; P M DiStefano; J DeMasi; E Middleton; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  1989-12       Impact factor: 6.875

View more
  5 in total

Review 1.  Nonlinear dynamics in clinical pharmacology: the paradigm of cortisol secretion and suppression.

Authors:  Aristides Dokoumetzidis; Athanassios Iliadis; Panos Macheras
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

2.  A pharmacokinetic simulation tool for inhaled corticosteroids.

Authors:  Benjamin Weber; Guenther Hochhaus
Journal:  AAPS J       Date:  2012-11-10       Impact factor: 4.009

3.  Cortisol response to individualised graded insulin infusions: a reproducible biomarker for CNS compounds inhibiting HPA activation.

Authors:  Christopher L H Chen; Brian A Willis; Louise Mooney; Guan Koon Ong; Chay Ngee Lim; Stephen L Lowe; Sitra Tauscher-Wisniewski; Gordon B Cutler; Stephen D Wiss
Journal:  Br J Clin Pharmacol       Date:  2010-12       Impact factor: 4.335

4.  Systemic exposure to fluticasone MDI delivered through antistatic chambers.

Authors:  Mai K Elmallah; Yasmeen Khan; Guenther Hochhaus; Jonathan J Shuster; Leslie Hendeles
Journal:  J Allergy Clin Immunol       Date:  2011-07-23       Impact factor: 10.793

5.  Assessment of the impact of dosing time on the pharmacokinetics/pharmacodynamics of prednisolone.

Authors:  Jian Xu; Julia Winkler; Sreedharan Nair Sabarinath; Hartmut Derendorf
Journal:  AAPS J       Date:  2008-06-25       Impact factor: 4.009

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.